Landesbank Baden Wurttemberg logo

Landesbank Baden Wurttemberg

Europe, Baden-Wurttemberg, Germany, Stuttgart

Description

LBBW Landesbank Baden-Wurttemberg is a both an universal bank and a commercial bank with a regional focus.

Investor Profile

Landesbank Baden Wurttemberg has made 9 investments, with 2 in the past 12 months and 11% as lead.

Stage Focus

  • Series C (22%)
  • Debt Financing (22%)
  • Series B (11%)
  • Series A (11%)
  • Seed (11%)
  • Pre Seed (11%)
  • Post Ipo Debt (11%)

Country Focus

  • Germany (78%)
  • United States (11%)
  • United Kingdom (11%)

Industry Focus

  • Software
  • Biopharma
  • Biotechnology
  • Pharmaceutical
  • Enterprise Software
  • Manufacturing
  • Information Technology
  • 3d Printing
  • 3d Technology
  • Industrial Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Landesbank Baden Wurttemberg frequently co-invest with?

Nextech Invest
Europe, Zurich, Switzerland, Zürich
Co-Investments: 1
LBBW VC
Europe, Baden-Wurttemberg, Germany, Stuttgart
Co-Investments: 1
Future Capital
Europe, Hessen, Germany, Frankfurt
Co-Investments: 2
EnBW New Ventures
Europe, Baden-Wurttemberg, Germany, Karlsruhe
Co-Investments: 1
AM Ventures
Europe, Bayern, Germany, Starnberg
Co-Investments: 1
Verve Ventures
Europe, Zug, Switzerland, Zug
Co-Investments: 1
coparion
Europe, Nordrhein-Westfalen, Germany, Cologne
Co-Investments: 1
TRUMPF Venture
Europe, Baden-Wurttemberg, Germany, Ditzingen
Co-Investments: 1
eCAPITAL ENTREPRENEURIAL PARTNERS
Europe, Nordrhein-Westfalen, Germany, Münster
Co-Investments: 1
UVC Partners
Europe, Bayern, Germany, Garching
Co-Investments: 1

Which angels does Landesbank Baden Wurttemberg often collaborate with?

Shared Deals: 1

What are some of recent deals done by Landesbank Baden Wurttemberg?

Community Fibre

London, England, United Kingdom

Community Fibre is a broadband company that exclusively serves London's residents and businesses.

InternetISPTelecommunications
Debt FinancingOct 23, 2024
Amount Raised: $161,456,779
Siemens

Munich, Bayern, Germany

Siemens empowers customers to transform the industries that form the backbone of economies: industry, transportation, buildings and grids.

Artificial Intelligence (AI)ConsultingCyber SecurityInternet of Things
Post Ipo DebtSep 4, 2024
Amount Raised: $332,397,082
1Komma5°

Hamburg, Hamburg, Germany

1Komma5° is an electricity company offering free electricity to all electric vehicle owners financed through trading using GHG quotas.

ManufacturingRenewable EnergySemiconductor
Debt FinancingDec 13, 2023
Amount Raised: $57,133,902
Swiat

Frankfurt, Hessen, Germany

Swiat is a fintech company that develops blockchain-based financial market infrastructure for regulated financial entities.

BlockchainCryptocurrencyFinancial ServicesFinTechSoftware
SeedJan 26, 2023
3YOURMIND

Berlin, Berlin, Germany

Automation software to manage additive manufacturing part selection, ordering and production workflows for Industry 4.0.

3D Printing3D TechnologyEnterprise SoftwareIndustrial ManufacturingManufacturingSoftware
Series AApr 22, 2021
Amount Raised: $12,400,000
LIMEBIRD

Hockenheim, Baden-Wurttemberg, Germany

Green Edge Cloud Computing

Cloud ComputingGreenTechInformation Technology
Pre SeedOct 17, 2020
Amount Raised: $234,300
Uptempo

Atlanta, Georgia, United States

Uptempo is an enterprise SaaS provider of Marketing Resource Management (MRM) systems.

Brand MarketingContent MarketingCRMDigital MarketingEnterprise Resource Planning (ERP)Enterprise SoftwareInformation TechnologyMarketingSaaSSoftware
Series CJun 27, 2018
Ganymed Pharmaceuticals

Mainz, Rheinland-Pfalz, Germany

Ganymed Pharmaceuticals is a biopharmaceutical developing therapeutic drugs designed to kill tumor cells without harming healthy tissues.

BiopharmaBiotechnologyPharmaceutical
Series CSep 24, 2007
Amount Raised: $47,482,979
Ganymed Pharmaceuticals

Mainz, Rheinland-Pfalz, Germany

Ganymed Pharmaceuticals is a biopharmaceutical developing therapeutic drugs designed to kill tumor cells without harming healthy tissues.

BiopharmaBiotechnologyPharmaceutical
Series BJul 6, 2005
Amount Raised: $14,400,000